US News in English<p>Arvinas presents promising Phase 1 data for ARV-102, a novel LRRK2 degrader - published 04 Apr 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-arvinas-presents-promising-phase-1-data-for-arv-102--a-novel-lrrk2-degrader-415360?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=415360" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-arvinas-</span><span class="invisible">presents-promising-phase-1-data-for-arv-102--a-novel-lrrk2-degrader-415360?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=415360</span></a></p>
Frühere Suchanfragen
Keine früheren Suchanfragen
Suchoptionen
Only available when logged in.
troet.cafe ist Teil eines dezentralisierten sozialen Netzwerks, angetrieben von Mastodon.
Hallo im troet.cafe!
Dies ist die derzeit größte deutschsprachige Mastodon Instanz zum tröten, neue Leute kennenlernen, sich auszutauschen und Spaß zu haben.
Verwaltet von:
Serverstatistik:
7,2 Tsd.aktive Profile
Mehr erfahren
troet.cafe: Über · Profilverzeichnis · Datenschutzerklärung
Mastodon: Über · App herunterladen · Tastenkombinationen · Quellcode anzeigen · v4.2.19
#clinicaltrials
13 Beiträge · 6 Beteiligte · 1 Beitrag heute
ASX Mkt. Sensitive<p>Mesoblast ( <a href="https://mastodon-grafa.social/tags/MSB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MSB</span></a> ) has released " Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs " on Fri 04 Apr at 09:33 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/mesoblast-ltd-3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/mesoblast-ltd-</span><span class="invisible">3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Remplir Cleared to Commence Sales in US$1.6B US Market " on Fri 04 Apr at 09:23 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
US News in English<p>Incannex completes Phase 2 enrollment in global RePOSA study for sleep apne... - published 03 Apr 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/Nasdaq" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Nasdaq</span></a> <a href="https://mastodon-grafa.social/tags/HealthCare" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HealthCare</span></a> <br><a href="https://grafa.com/news/health-incannex-completes-phase-2-enrollment-in-global-reposa-study-for-sleep-apnea-treatment-414183?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414183" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-incannex</span><span class="invisible">-completes-phase-2-enrollment-in-global-reposa-study-for-sleep-apnea-treatment-414183?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414183</span></a></p>
US News in English<p>Enlivex Therapeutics initiates Phase I trial for TMJ osteoarthritis treatme... - published 03 Apr 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-enlivex-therapeutics-initiates-phase-i-trial-for-tmj-osteoarthritis-treatment-with-allocetra--414172?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414172" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-enlivex-</span><span class="invisible">therapeutics-initiates-phase-i-trial-for-tmj-osteoarthritis-treatment-with-allocetra--414172?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414172</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Trading Halt " on Thu 03 Apr at 09:06 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " RC220 Phase 1 Trial Opens for Patient Enrolment " on Thu 03 Apr at 08:57 AEST <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Bioxyne ( <a href="https://mastodon-grafa.social/tags/BXN" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BXN</span></a> ) has released " BXN Signs Exclusive $7m Manufacturing and Supply Agreement " on Thu 03 Apr at 08:32 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/bioxyne-ltd-6076-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/bioxyne-ltd-60</span><span class="invisible">76-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx</span></a></p>
ASX Mkt. Sensitive<p>BlinkLab ( <a href="https://mastodon-grafa.social/tags/BB1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BB1</span></a> ) has released " BlinkLab Surpasses Key Milestone in Pivotal U.S. Trial " on Tue 01 Apr at 09:20 AEST <a href="https://mastodon-grafa.social/tags/Facebook" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Facebook</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/blinklab-fpo-26655-bb1.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bb1.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/blinklab-fpo-2</span><span class="invisible">6655-bb1.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bb1.asx</span></a></p>
ASX Mkt. Sensitive<p>Opthea ( <a href="https://mastodon-grafa.social/tags/OPT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OPT</span></a> ) has released " Opthea Announces Decision to Discontinue Wet AMD Trials " on Mon 31 Mar at 12:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/opthea-ltd-3521-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/opthea-ltd-352</span><span class="invisible">1-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx</span></a></p>
ASX Mkt. Sensitive<p>Mesoblast ( <a href="https://mastodon-grafa.social/tags/MSB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MSB</span></a> ) has released " First Children To Begin Treatment, Medicaid Covers Ryoncil " on Mon 31 Mar at 09:59 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/mesoblast-ltd-3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/mesoblast-ltd-</span><span class="invisible">3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " First Cohort Dosed in Nyradas Phase I Clinical Trial " on Mon 31 Mar at 09:52 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
ASX Mkt. Sensitive<p>Archer Materials ( <a href="https://mastodon-grafa.social/tags/AXE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AXE</span></a> ) has released " AXE partners with Hylid Diagnostics for Biochip development " on Mon 31 Mar at 09:11 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/rise" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>rise</span></a> <br><a href="https://grafa.com/asset/archer-exploration-ltd-5699-axe.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=axe.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/archer-explora</span><span class="invisible">tion-ltd-5699-axe.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=axe.asx</span></a></p>
asx_news_de<p>Avecho Biotechnology schließt einen Vertrag über 3 Millionen US-Dollar mit ... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/de-health-avecho-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408263?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=408263" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/de-health-avech</span><span class="invisible">o-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408263?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=408263</span></a></p>
ASX News in English<p>Avecho Biotechnology wins US$3M deal with Sandoz for exclusive CBD insomnia... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/health-avecho-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408231?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=408231" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-avecho-b</span><span class="invisible">iotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408231?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=408231</span></a></p>
Technology Tales<p>The future of statistical programming recruitment lies in adaptability and expertise beyond SAS. As clinical trials become more complex, the demand for skills in automation, real-world evidence, and AI integration is rising. Companies must update their hiring strategies to ensure compliance and efficiency, focusing on programmers with the right hybrid skills. <a href="https://mstdn.social/tags/StatisticalProgramming" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>StatisticalProgramming</span></a> <a href="https://mstdn.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mstdn.social/tags/AI" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AI</span></a> <a href="https://mstdn.social/tags/Recruitment" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Recruitment</span></a> <a href="https://www.warmanobrien.com/resources/blog/top-5-skills-defining-statistical-programming-recruitment/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">warmanobrien.com/resources/blo</span><span class="invisible">g/top-5-skills-defining-statistical-programming-recruitment/</span></a></p>
US News in English<p>Septerna unveils corporate overview and 2024 financial results - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-septerna-unveils-corporate-overview-and-2024-financial-results-407988?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407988" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-septerna</span><span class="invisible">-unveils-corporate-overview-and-2024-financial-results-407988?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407988</span></a></p>
US News in English<p>Alterity Therapeutics completes Phase 2 open-label study for advanced MSA t... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-alterity-therapeutics-completes-phase-2-open-label-study-for-advanced-msa-treatment-407896?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407896" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-alterity</span><span class="invisible">-therapeutics-completes-phase-2-open-label-study-for-advanced-msa-treatment-407896?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407896</span></a></p>
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " Race Initiates First AU Site for Phase 1 Solid Tumour Trial " on Thu 27 Mar at 15:53 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Actinogen Medical ( <a href="https://mastodon-grafa.social/tags/ACW" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ACW</span></a> ) has released " ACW conducts Type C meeting with FDA regarding depression " on Thu 27 Mar at 11:58 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/actinogen-medical-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/actinogen-medi</span><span class="invisible">cal-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx</span></a></p>
EntdeckenLive-Feeds
Melde dich an, um Profilen oder Hashtags zu folgen, Beiträge zu favorisieren, zu teilen und auf sie zu antworten. Du kannst auch von deinem Konto aus auf einem anderen Server interagieren.
Konto erstellenAnmeldenZum Hochladen hereinziehen